Leukemia Insights - Spring 2010
The key to improving the prognosis of adult ALL will be to further define the biological subtypes that are amenable to incorporation of targeted agents into the chemotherapy programs. Continued development of more effective and novel therapeutics that either target or circumvent mechanisms of resistance will be paramount. Future research should focus on the interactions of lymphoblasts with their marrow microenvironment by using agents that exploit them (e.g. inhibitors of the chemokine receptor CXCR4 such as plerixifor which is currently approved for stem cell mobilization or use of prodrugs such as PR104 or TH-302 which are activated in the hypoxic marrow “niches”). A potentially curative strategy includes targeting all of the unique mechanisms which promote lymphoblast survival, and will likely result in development of a tailored multi-targeted chemotherapy-based “cocktails” designed to eradicate all of the leukemia subclones.
Completing these studies in a timely manner will allow us to move quickly on positive leads. We appreciate referrals and will make every effort to continue as much of the care as possible through the referring oncologist whenever feasible. We will also keep you apprised of the patient’s progress once they are enrolled on a clinical trial.
In This Issue
- Salvage Strategies for Relapsed or Refractory Acute Lymphoblastic Leukemia